Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

After-hours movers: HP Inc., Dell Technologies, Workday and more

Published 2024-11-26, 04:48 p/m
© Shutterstock
DELL
-
ADSK
-
HPQ
-
JWN
-
URBN
-
WDAY
-
AMBA
-
PTCT
-
CRWD
-

After-Hours Stock Movers:

HP Inc. (NYSE:HPQ) fell 7.5% after it issued lackluster guidance. For fiscal 2025, HP estimates non-GAAP diluted net EPS to be in the range of $3.45 to $3.75, about in-line with consensus.

Dell Technologies (NYSE:DELL) fell 6% despite beating estimates for third quarter EPS and revenue. Revenue was $24.4 billion, up 10% year over year. Diluted earnings per share was $1.58, and non-GAAP diluted earnings per share was $2.15, up 16% and 14% year over year, respectively.

Autodesk (NASDAQ:ADSK) fell 7.7% despite beating estimates and raising guidance. Third quarter total revenue increased 11% to $1.57 billion.

Workday (NASDAQ:WDAY) fell 8% despite beating third quarter results, after it issued disappointing guidance. It sees Q4 subscription revenue of $2.025 billion, slightly below consensus of $2.04 billion.

CrowdStrike (NASDAQ:CRWD) fell 2.1% after beating third quarter results. Total revenue was $1,010.2 million, a 29% increase, compared to $786.0 million in the third quarter of fiscal 2024. Subscription revenue was $962.7 million, a 31% increase, compared to $733.5 million in the third quarter of fiscal 2024.

Urban Outfitters (NASDAQ:URBN) rose 5% after it published strong quarterly EPS and revenue. Total Company net sales for the three months ended October 31, 2024, increased 6.3% to a record $1.36 billion.

Nordstrom (NYSE:JWN) fell 1% despite beating estimates for its third quarter. Total Company net sales increased 4.6 percent and comparable sales increased 4.0 percent compared with the same period in fiscal 2023.

Ambarella (NASDAQ:AMBA) surged 25% after results beat the average analyst estimate and it issued strong guidance for the final quarter of the year. Revenue for the third quarter of fiscal 2025 was $82.7 million, up 63% from $50.6 million in the same period in fiscal 2024.

PTC Therapeutics (NASDAQ:PTCT) fell 13% after its Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing disease progression on the composite ALSFRS-R and mortality analysis.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.